847 related articles for article (PubMed ID: 22738801)
1. Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study.
Aravind SR; Ismail SB; Balamurugan R; Gupta JB; Wadhwa T; Loh SM; Suryawanshi S; Davies MJ; Girman CJ; Katzeff HL; Radican L; Engel SS; Wolthers T
Curr Med Res Opin; 2012 Aug; 28(8):1289-96. PubMed ID: 22738801
[TBL] [Abstract][Full Text] [Related]
2. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial.
Al Sifri S; Basiounny A; Echtay A; Al Omari M; Harman-Boehm I; Kaddaha G; Al Tayeb K; Mahfouz AS; Al Elq A; Radican L; Ozesen C; Katzeff HL; Musser BJ; Suryawanshi S; Girman CJ; Davies MJ; Engel SS;
Int J Clin Pract; 2011 Nov; 65(11):1132-40. PubMed ID: 21951832
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
[TBL] [Abstract][Full Text] [Related]
5. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
Brazg R; Xu L; Dalla Man C; Cobelli C; Thomas K; Stein PP
Diabetes Obes Metab; 2007 Mar; 9(2):186-93. PubMed ID: 17300594
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study.
Hassanein M; Hanif W; Malik W; Kamal A; Geransar P; Lister N; Andrews C; Barnett A
Curr Med Res Opin; 2011 Jul; 27(7):1367-74. PubMed ID: 21568833
[TBL] [Abstract][Full Text] [Related]
7. Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone.
Srivastava S; Saxena GN; Keshwani P; Gupta R
J Assoc Physicians India; 2012 Mar; 60():27-30. PubMed ID: 22799111
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea.
Mohan V; Yang W; Son HY; Xu L; Noble L; Langdon RB; Amatruda JM; Stein PP; Kaufman KD
Diabetes Res Clin Pract; 2009 Jan; 83(1):106-16. PubMed ID: 19097665
[TBL] [Abstract][Full Text] [Related]
9. Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA(1c) value.
Krobot KJ; Ferrante SA; Davies MJ; Seck T; Meininger GE; Williams-Herman D; Kaufman KD; Goldstein BJ
Curr Med Res Opin; 2012 Aug; 28(8):1281-7. PubMed ID: 22697277
[TBL] [Abstract][Full Text] [Related]
10. Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement.
Alba M; Sheng D; Guan Y; Williams-Herman D; Larson P; Sachs JR; Thornberry N; Herman G; Kaufman KD; Goldstein BJ
Curr Med Res Opin; 2009 Oct; 25(10):2507-14. PubMed ID: 19691426
[TBL] [Abstract][Full Text] [Related]
11. The effect of vildagliptin relative to sulfonylurea as dual therapy with metformin (or as monotherapy) in Muslim patients with type 2 diabetes fasting during Ramadan in the Middle East: the VIRTUE study.
Hassoun AA; Al-Arouj M; Ibrahim M
Curr Med Res Opin; 2017 Jan; 33(1):161-167. PubMed ID: 27684469
[TBL] [Abstract][Full Text] [Related]
12. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
[TBL] [Abstract][Full Text] [Related]
13. Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database.
Zhang Q; Rajagopalan S; Mavros P; Engel SS; Davies MJ; Yin D; Radican L
Curr Med Res Opin; 2010 Jul; 26(7):1697-703. PubMed ID: 20465367
[TBL] [Abstract][Full Text] [Related]
14. Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational study.
Aravind SR; Al Tayeb K; Ismail SB; Shehadeh N; Kaddaha G; Liu R; Balshaw R; Lesnikova N; Heisel O; Girman CJ; Musser BJ; Davies MJ; Katzeff HL; Engel SS; Radican L;
Curr Med Res Opin; 2011 Jun; 27(6):1237-42. PubMed ID: 21506631
[TBL] [Abstract][Full Text] [Related]
15. Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan.
Bakiner O; Ertorer ME; Bozkirli E; Tutuncu NB; Demirag NG
Acta Diabetol; 2009 Mar; 46(1):63-5. PubMed ID: 18825302
[TBL] [Abstract][Full Text] [Related]
16. An open label comparative study of glimepiride versus repaglinide in type 2 diabetes mellitus Muslim subjects during the month of Ramadan.
Anwar A; Azmi KN; Hamidon BB; Khalid BA
Med J Malaysia; 2006 Mar; 61(1):28-35. PubMed ID: 16708731
[TBL] [Abstract][Full Text] [Related]
17. Comparative studies of dipeptidyl peptidase 4 inhibitor vs sulphonylurea among Muslim Type 2 diabetes patients who fast in the month of Ramadan: A systematic review and meta-analysis.
Loh HH; Yee A; Loh HS; Sukor N; Kamaruddin NA
Prim Care Diabetes; 2016 Jun; 10(3):210-9. PubMed ID: 26392074
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes.
Pérez-Monteverde A; Seck T; Xu L; Lee MA; Sisk CM; Williams-Herman DE; Engel SS; Kaufman KD; Goldstein BJ
Int J Clin Pract; 2011 Sep; 65(9):930-8. PubMed ID: 21849007
[TBL] [Abstract][Full Text] [Related]
19. Treatment adherence with vildagliptin compared to sulphonylurea as add-on to metformin in Muslim patients with type 2 diabetes mellitus fasting during Ramadan.
Hanif W; Malik W; Hassanein M; Kamal A; Geransar P; Andrews C; Azam M; Barnett AH
Curr Med Res Opin; 2013 Jul; 29(7):807-11. PubMed ID: 23659561
[TBL] [Abstract][Full Text] [Related]
20. The E23K variant of KCNJ11 and the risk for severe sulfonylurea-induced hypoglycemia in patients with type 2 diabetes.
Holstein A; Hahn M; Stumvoll M; Kovacs P
Horm Metab Res; 2009 May; 41(5):387-90. PubMed ID: 19214942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]